Assuntos
COVID-19/complicações , Doença Crônica , Serviços Preventivos de Saúde/organização & administração , Saúde Pública , COVID-19/epidemiologia , COVID-19/prevenção & controle , Doença Crônica/epidemiologia , Doença Crônica/prevenção & controle , Humanos , Colaboração Intersetorial , Saúde Pública/métodos , Saúde Pública/tendências , Fatores de Risco , SARS-CoV-2 , Determinantes Sociais da Saúde , Seguridade Social , Fatores Socioeconômicos , Síndrome de COVID-19 Pós-AgudaAssuntos
COVID-19 , Necessidades e Demandas de Serviços de Saúde/tendências , Doenças não Transmissíveis , Serviços Preventivos de Saúde , Medição de Risco/tendências , Determinantes Sociais da Saúde/tendências , COVID-19/epidemiologia , COVID-19/prevenção & controle , Estilo de Vida Saudável , Humanos , Doenças não Transmissíveis/epidemiologia , Doenças não Transmissíveis/prevenção & controle , Doenças não Transmissíveis/psicologia , Serviços Preventivos de Saúde/métodos , Serviços Preventivos de Saúde/organização & administração , Serviços Preventivos de Saúde/normas , Serviços Preventivos de Saúde/tendências , Medicina Preventiva/métodos , Fatores de Risco , Comportamento de Redução do Risco , SARS-CoV-2 , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: Meta-analyses of observational studies have shown that women with a shorter interpregnancy interval (the time from delivery to start of a subsequent pregnancy) are more likely to experience adverse pregnancy outcomes, such as preterm delivery or small for gestational age birth, than women who space their births further apart. However, the studies used to inform these estimates have methodological shortcomings. METHODS: In this commentary, we summarise the discussions of an expert workgroup describing good practices for the design, analysis, and interpretation of observational studies of interpregnancy interval and adverse perinatal health outcomes. RESULTS: We argue that inferences drawn from research in this field will be improved by careful attention to elements such as: (a) refining the research question to clarify whether the goal is to estimate a causal effect vs describe patterns of association; (b) using directed acyclic graphs to represent potential causal networks and guide the analytic plan of studies seeking to estimate causal effects; (c) assessing how miscarriages and pregnancy terminations may have influenced interpregnancy interval classifications; (d) specifying how key factors such as previous pregnancy loss, pregnancy intention, and maternal socio-economic position will be considered; and (e) examining if the association between interpregnancy interval and perinatal outcome differs by factors such as maternal age. CONCLUSION: This commentary outlines the discussions of this recent expert workgroup, and describes several suggested principles for study design and analysis that could mitigate many potential sources of bias.
Assuntos
Intervalo entre Nascimentos , Estudos Observacionais como Assunto/métodos , Resultado da Gravidez , Aborto Espontâneo/epidemiologia , Interpretação Estatística de Dados , Feminino , Humanos , Recém-Nascido Pequeno para a Idade Gestacional , Idade Materna , Paridade , Gravidez , Nascimento Prematuro/epidemiologia , Nascimento Prematuro/etiologia , Fatores Socioeconômicos , Fatores de TempoAssuntos
Comorbidade/tendências , Doença Crônica/epidemiologia , Feminino , Humanos , Masculino , Medicare , Prevalência , Pesquisa , Estados Unidos/epidemiologiaRESUMO
With non-communicable conditions accounting for nearly two-thirds of deaths worldwide, the emergence of chronic diseases as the predominant challenge to global health is undisputed. In the USA, chronic diseases are the main causes of poor health, disability, and death, and account for most of health-care expenditures. The chronic disease burden in the USA largely results from a short list of risk factors--including tobacco use, poor diet and physical inactivity (both strongly associated with obesity), excessive alcohol consumption, uncontrolled high blood pressure, and hyperlipidaemia--that can be effectively addressed for individuals and populations. Increases in the burden of chronic diseases are attributable to incidence and prevalence of leading chronic conditions and risk factors (which occur individually and in combination), and population demographics, including ageing and health disparities. To effectively and equitably address the chronic disease burden, public health and health-care systems need to deploy integrated approaches that bundle strategies and interventions, address many risk factors and conditions simultaneously, create population-wide changes, help the population subgroups most affected, and rely on implementation by many sectors, including public-private partnerships and involvement from all stakeholders. To help to meet the chronic disease burden, the US Centers for Disease Control and Prevention (CDC) uses four cross-cutting strategies: (1) epidemiology and surveillance to monitor trends and inform programmes; (2) environmental approaches that promote health and support healthy behaviours; (3) health system interventions to improve the effective use of clinical and other preventive services; and (4) community resources linked to clinical services that sustain improved management of chronic conditions. Establishment of community conditions to support healthy behaviours and promote effective management of chronic conditions will deliver healthier students to schools, healthier workers to employers and businesses, and a healthier population to the health-care system. Collectively, these four strategies will prevent the occurrence of chronic diseases, foster early detection and slow disease progression in people with chronic conditions, reduce complications, support an improved quality of life, and reduce demand on the health-care system. Of crucial importance, with strengthened collaboration between the public health and health-care sectors, the health-care system better uses prevention and early detection services, and population health is improved and sustained by solidifying collaborations between communities and health-care providers. This collaborative approach will improve health equity by building communities that promote health rather than disease, have more accessible and direct care, and focus the health-care system on improving population health.
Assuntos
Causas de Morte , Doença Crônica/epidemiologia , Doença Crônica/prevenção & controle , Pessoas com Deficiência/estatística & dados numéricos , Comportamentos Relacionados com a Saúde , Acessibilidade aos Serviços de Saúde , Saúde Pública , Comportamento de Redução do Risco , Consumo de Bebidas Alcoólicas , Causas de Morte/tendências , Doença Crônica/economia , Doença Crônica/mortalidade , Efeitos Psicossociais da Doença , Ambiente Controlado , Comportamento Alimentar , Acessibilidade aos Serviços de Saúde/tendências , Necessidades e Demandas de Serviços de Saúde , Humanos , Hiperlipidemias/epidemiologia , Hipertensão/epidemiologia , Obesidade/epidemiologia , Saúde Pública/normas , Saúde Pública/tendências , Parcerias Público-Privadas , Características de Residência , Comportamento Sedentário , Tabagismo/epidemiologia , Estados Unidos/epidemiologiaAssuntos
Doenças Cardiovasculares/prevenção & controle , Programas Nacionais de Saúde , Padrões de Prática Médica , Serviços Preventivos de Saúde , Saúde Pública , Anti-Hipertensivos/uso terapêutico , Aspirina/uso terapêutico , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/mortalidade , Competência Clínica , Determinação de Ponto Final , Medicina Baseada em Evidências , Política de Saúde , Promoção da Saúde , Humanos , Hipolipemiantes/uso terapêutico , Incidência , Programas Nacionais de Saúde/legislação & jurisprudência , Inibidores da Agregação Plaquetária/uso terapêutico , Serviços Preventivos de Saúde/legislação & jurisprudência , Prognóstico , Desenvolvimento de Programas , Saúde Pública/legislação & jurisprudência , Medição de Risco , Fatores de Risco , Comportamento de Redução do Risco , Abandono do Hábito de Fumar , Estados Unidos , Redução de PesoRESUMO
Systematic reviews are generating valuable scientific knowledge about the impact of public health laws, but this knowledge is not readily accessible to policy makers. We identified 65 systematic reviews of studies on the effectiveness of 52 public health laws: 27 of those laws were found effective, 23 had insufficient evidence to judge effectiveness, 1 was harmful, and 1 was found to be ineffective. This is a valuable, scientific foundation-that uses the highest relevant standard of evidence-for the role of law as a public health tool. Additional primary studies and systematic reviews are needed to address significant gaps in knowledge about the laws' public health impact, as are energetic, sustained initiatives to make the findings available to public policy makers.
Assuntos
Regulamentação Governamental , Política de Saúde/legislação & jurisprudência , Prática de Saúde Pública , Coleta de Dados , Humanos , Saúde Pública/legislação & jurisprudênciaAssuntos
Planejamento em Saúde Comunitária , Promoção da Saúde , Neoplasias/prevenção & controle , Adulto , Idoso , Análise Custo-Benefício , Medicina Baseada em Evidências , Feminino , Humanos , Masculino , Programas de Rastreamento , Pessoa de Meia-Idade , Neoplasias/diagnóstico , Guias de Prática Clínica como Assunto , Literatura de Revisão como Assunto , Estados UnidosAssuntos
Promoção da Saúde/métodos , Neoplasias/prevenção & controle , Análise Custo-Benefício , Medicina Baseada em Evidências , Feminino , Humanos , Masculino , Programas de Rastreamento/economia , Programas de Rastreamento/normas , Neoplasias/diagnóstico , Neoplasias/economia , Projetos de Pesquisa , Literatura de Revisão como Assunto , Estados UnidosRESUMO
Most major medical organizations recommend routine screening for breast, cervical, and colorectal cancers. Screening can lead to early detection of these cancers, resulting in reduced mortality. Yet not all people who should be screened are screened, either regularly or, in some cases, ever. This report presents the results of systematic reviews of effectiveness, applicability, economic efficiency, barriers to implementation, and other harms or benefits of interventions designed to increase screening for breast, cervical, and colorectal cancers by increasing community demand for these services. Evidence from these reviews indicates that screening for breast cancer (mammography) and cervical cancer (Pap test) has been effectively increased by use of client reminders, small media, and one-on-one education. Screening for colorectal cancer by fecal occult blood test has been increased effectively by use of client reminders and small media. Additional research is needed to determine whether client incentives, group education, and mass media are effective in increasing use of any of the three screening tests; whether one-on-one education increases screening for colorectal cancer; and whether any demand-enhancing interventions are effective in increasing the use of other colorectal cancer screening procedures (i.e., flexible sigmoidoscopy, colonoscopy, double contrast barium enema). Specific areas for further research are also suggested in this report.
Assuntos
Participação da Comunidade , Promoção da Saúde/métodos , Necessidades e Demandas de Serviços de Saúde , Neoplasias/prevenção & controle , Ensaios Clínicos como Assunto , Medicina Baseada em Evidências , Feminino , Humanos , Masculino , Programas de Rastreamento , Neoplasias/diagnóstico , Estados UnidosAssuntos
Serviços de Saúde da Criança/estatística & dados numéricos , Serviços de Assistência Domiciliar/estatística & dados numéricos , Violência/prevenção & controle , Serviços de Saúde da Criança/economia , Pré-Escolar , Análise Custo-Benefício , Medicina Baseada em Evidências/métodos , Diretrizes para o Planejamento em Saúde , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Programas Gente Saudável , Serviços de Assistência Domiciliar/economia , Humanos , Lactente , Recém-Nascido , Avaliação de Processos e Resultados em Cuidados de Saúde/métodos , Avaliação de Programas e Projetos de Saúde/métodos , Estados UnidosAssuntos
Política de Saúde/legislação & jurisprudência , Formulação de Políticas , Administração em Saúde Pública/legislação & jurisprudência , Saúde Pública/legislação & jurisprudência , Ciência/legislação & jurisprudência , Pesquisa Biomédica/economia , Comportamento Cooperativo , Tomada de Decisões Gerenciais , Medicina Baseada em Evidências , Humanos , Disseminação de Informação , Política , Opinião Pública , Religião e Medicina , Medição de Risco , Estados UnidosRESUMO
Interest in informed decision making (IDM) has grown in recent years. Greater patient involvement in decision making is consistent with recommendations to improve health care quality. This report provides an overview of IDM; clarifies the differences between IDM, shared decision making (SDM), and informed consent; and reviews the evidence to date about IDM for cancer screening. The authors also make recommendations for research. We define IDM as occurring when an individual understands the disease or condition being addressed and comprehends what the clinical service involves, including its benefits, risks, limitations, alternatives, and uncertainties; has considered his or her preferences and makes a decision consistent with them; and believes he or she has participated in decision making at the level desired. IDM interventions are used to facilitate informed decisions. The authors reviewed the evidence to date for IDM and cancer screening based primarily on published meta-analyses and a recent report for the Centers for Disease Control and Prevention's Guide to Community Preventive Services. IDM and SDM interventions, such as decision aids, result in improved knowledge, beliefs, risk perceptions, and combinations of these. Little or no evidence exists, however, regarding whether these interventions result in 1) participation in decision making at a level consistent with patient preferences or 2) effects on patient satisfaction with the decision-making process. These variables generally either were not assessed or were not reported in the articles reviewed. Results of interventions on uptake of screening were variable. After exposure to IDM/SDM interventions, most studies showed small decreases in prostate cancer screening, whereas four studies on breast and colorectal cancer screening showed small increases. Few data are available by which to evaluate current practices in cancer screening IDM. Patient participation in IDM should be facilitated for those who prefer it. More research is needed to assess the benefits of IDM/SDM interventions and to tailor interventions to individuals who are most likely to desire and benefit from them. There are many system barriers to IDM/SDM and few tools. More work is needed in this area as well. In addition, research is needed to learn how to incorporate IDM into ongoing clinical practice and to determine whether there are unintended negative consequences of IDM.
Assuntos
Tomada de Decisões , Atenção à Saúde/organização & administração , Consentimento Livre e Esclarecido , Programas de Rastreamento , Neoplasias/diagnóstico , Serviços de Saúde Comunitária/organização & administração , Humanos , Neoplasias/prevenção & controleRESUMO
Cost-effectiveness analyses (CEAs) can help to quantify the contribution of the promotion of a screening program to increased participation in screening. The cost-effectiveness (C/E) of screening promotion depends in large part on the endpoints of interest. At the most fundamental level, the C/E of a strategy for promoting screening would focus on the attendance rate, or cost per person screened, and the C/E would be influenced by the costs of promotion, as well as by the size and responsiveness of the target population. In addition, the costs of screening promotion (measured as the cost per additional participant in screening) can be included in a CEA estimate of the screening technology. In this case, depending on the efficacy of the screening test and the costs and influence of the promotion, the C/E of screening may improve or become poorer. In the current study, the authors reviewed the literature on the C/E of cancer screening promotion. The following lessons were learned regarding the C/E of screening and its promotion: 1) high-quality information on the C/E of screening is increasingly available; 2) cost-effective promotion of screening is dependent on cost-effective screening strategies; 3) quality-of-life effects may be important in assessing the overall C/E of screening programs; 4) research efforts aimed at identifying cost-effective approaches to screening promotion are useful but sparse; 5) C/E studies should be better incorporated into well designed effectiveness research efforts; 6) variations in C/E according to intervention characteristics, population characteristics, and context should be evaluated in greater depth; 7) the long-term effects of screening promotion are critical to assessing C/E; 8) the effects of promotion on costs of screening must be better understood; and 9) CEA must be interpreted in light of other information. The authors showed that CEA can be a valuable tool for understanding the merits of health promotion interventions and that CEA is particularly valuable in identifying screening strategies that might be promoted most cost-effectively.
Assuntos
Análise Custo-Benefício , Promoção da Saúde/economia , Programas de Rastreamento/economia , Neoplasias/economia , Humanos , Neoplasias/diagnóstico , Neoplasias/prevenção & controle , Anos de Vida Ajustados por Qualidade de Vida , Serviços de Saúde Rural/economia , Marketing Social , Recursos HumanosRESUMO
Users of clinical practice guidelines and other recommendations need to know how much confidence they can place in the recommendations. Systematic and explicit methods of making judgments can reduce errors and improve communication. We have developed a system for grading the quality of evidence and the strength of recommendations that can be applied across a wide range of interventions and contexts. In this article we present a summary of our approach from the perspective of a guideline user. Judgments about the strength of a recommendation require consideration of the balance between benefits and harms, the quality of the evidence, translation of the evidence into specific circumstances, and the certainty of the baseline risk. It is also important to consider costs (resource utilisation) before making a recommendation. Inconsistencies among systems for grading the quality of evidence and the strength of recommendations reduce their potential to facilitate critical appraisal and improve communication of these judgments. Our system for guiding these complex judgments balances the need for simplicity with the need for full and transparent consideration of all important issues.